Leerink Swann Weighs in on Karyopharm Therapeutics Inc’s Q1 2017 Earnings (KPTI)

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Analysts at Leerink Swann issued their Q1 2017 earnings per share estimates for shares of Karyopharm Therapeutics in a research note issued on Thursday. Leerink Swann analyst M. Schmidt anticipates that the brokerage will earn ($0.62) per share for the quarter. Leerink Swann also issued estimates for Karyopharm Therapeutics’ Q2 2017 earnings at ($0.63) EPS, Q3 2017 earnings at ($0.65) EPS and Q4 2017 earnings at ($0.66) EPS.

Your IP Address:

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

KPTI has been the topic of several other research reports. HC Wainwright restated a “buy” rating and issued a $14.00 target price (down previously from $15.00) on shares of Karyopharm Therapeutics in a research note on Tuesday, March 7th. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday, November 22nd. Jefferies Group LLC restated a “buy” rating and issued a $14.00 target price (up previously from $12.00) on shares of Karyopharm Therapeutics in a research note on Sunday, December 4th. Canaccord Genuity restated a “buy” rating and issued a $20.00 target price on shares of Karyopharm Therapeutics in a research note on Monday, March 13th. Finally, Wedbush restated an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Saturday, March 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Karyopharm Therapeutics presently has an average rating of “Buy” and an average target price of $13.76.

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 10.67 on Monday. The firm’s market cap is $440.06 million. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The stock has a 50 day moving average of $10.71 and a 200 day moving average of $9.69.

Hedge funds and other institutional investors have recently modified their holdings of the company. Palo Alto Investors LLC increased its position in shares of Karyopharm Therapeutics by 3.7% in the fourth quarter. Palo Alto Investors LLC now owns 3,200,396 shares of the company’s stock valued at $30,084,000 after buying an additional 114,547 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares during the period. Trexquant Investment LP bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $273,000. Dimensional Fund Advisors LP increased its position in shares of Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock valued at $2,454,000 after buying an additional 202,714 shares during the period. Finally, State Street Corp increased its position in shares of Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock valued at $3,820,000 after buying an additional 25,015 shares during the period. Institutional investors and hedge funds own 56.97% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.